Prognostic polypeptide blood plasma biomarkers of Alzheimer's disease progression
H Yang, Y Lyutvinskiy, SK Herukka… - Journal of …, 2014 - content.iospress.com
H Yang, Y Lyutvinskiy, SK Herukka, H Soininen, D Rutishauser, RA Zubarev
Journal of Alzheimer's Disease, 2014•content.iospress.comBackground: Patients with mild cognitive impairment (MCI) have varying risks of progression
to Alzheimer's disease (AD). Objective: To test the utility of the relative abundances of blood
plasma polypeptides for predicting the risk of AD progression. Methods: 119 blood plasma
samples of patients with MCI with different outcomes (stable MCI and progressive MCI) were
analyzed by untargeted, label-free shotgun proteomics. Predictive biomarkers of progressive
MCI were selected by multivariate analysis, followed by cross-validation of the predictive …
to Alzheimer's disease (AD). Objective: To test the utility of the relative abundances of blood
plasma polypeptides for predicting the risk of AD progression. Methods: 119 blood plasma
samples of patients with MCI with different outcomes (stable MCI and progressive MCI) were
analyzed by untargeted, label-free shotgun proteomics. Predictive biomarkers of progressive
MCI were selected by multivariate analysis, followed by cross-validation of the predictive …
Abstract
Background:
Patients with mild cognitive impairment (MCI) have varying risks of progression to Alzheimer’s disease (AD).
Objective:
To test the utility of the relative abundances of blood plasma polypeptides for predicting the risk of AD progression.
Methods:
119 blood plasma samples of patients with MCI with different outcomes (stable MCI and progressive MCI) were analyzed by untargeted, label-free shotgun proteomics. Predictive biomarkers of progressive MCI were selected by multivariate analysis, followed by cross-validation of the predictive model.
Results:
The best model demonstrated the accuracy of ca. 79% in predicting progressive MCI. Sex differences of the predictive biomarkers were also assessed. We have identified some sex-specific protein biomarkers, eg, alpha-2-macrogloblin (A2M), which strongly correlates with female AD progression but not with males.
Conclusion:
Significant sex bias in AD-specific biomarkers underscores the necessity of selecting sex-balanced cohort in AD biomarker studies, or using sex-specific models. Blood protein biomarkers are found to be promising for predicting AD progression in clinical settings.
content.iospress.com